Clinical Trial Update: Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Rituximab for humoral chronic rejection after renal transplantation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allograft Nephropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Technical University of Munich | Conditions: Grafting, Renal Transplantation | Phase 2 | Status: TERMINATED